The partnership aims to advance the development of FimmCyte’s first-in-class antibody, ‘FMC2’, for the treatment of endometriosis.

This collaboration builds on Richter’s recent expansion of its novel drug development capabilities, including the establishment of its women’s health original research and development hub in Belgium, which will serve as a key centre for advancing the program.

Under the agreement, the collaboration will focus on joint research and development activities aimed at advancing FMC2, a potential disease-modifying antibody to the clinic. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. This license will automatically become effective if Richter elects to exercise its exclusive option at any time prior to the initiation of the first-in-human clinical study.

This structure provides a clear and efficient pathway from preclinical research through global commercialization, eliminating the need for new license negotiations and enabling rapid transition into clinical development. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.

This partnership brings together Richter’s expertise in women’s health and FimmCyte’s cutting-edge immunotherapy and proprietary antibody technology to advance innovation and bring to market a first potential disease-modifying treatment for endometriosis.

According to the World Health Organization, around 190 million women worldwide are affected by endometriosis. Despite its prevalence, there is currently no cure for the condition, and existing treatments focus solely on symptom management[1]. This partnership with FimmCyte offers a unique opportunity to reshape the endometriosis treatment landscape, through meaningful innovation and truly patient-centered solutions.

Dr. Péter Turek, Head of Women’s Healthcare Business Unit at Richter, commented: “This research collaboration marks an important milestone in the execution of our strategy and reinforces our ambition to become a leader in women’s healthcare. By advancing innovative research in endometriosis, an area with significant unmet medical need, we are strengthening our pipeline while working to deliver transformative solutions that can improve the quality of life of millions of women worldwide.”

Dr. Mohaned Shilaih, CEO of FimmCyte, added: “Gedeon Richter is one of the few true leaders in women’s health, and this partnership is a powerful validation of FimmCyte’s pioneering approach: using precision immunotherapy to address the root cause of complex chronic conditions, starting with endometriosis. By combining our innovation with Gedeon Richter’s women’s health leadership, we aim to bring a first‑in‑class, disease‑modifying therapy to patients quicker”.

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation.

About Fimmcyte